PHARMACY

MinuteClinic opens new clinics in Md. Target stores

BY Gina Acosta

WOONSOCKET, R.I. — MinuteClinic has opened eight new locations inside Target stores in Maryland, including six in the Baltimore metropolitan area.

The clinics – located in stores in Annapolis, Baltimore (Canton), Bel Air, Cockeysville, Ellicott City, Nottingham, Silver Spring and Towson – have been rebranded and converted to MinuteClinic. There are now 43 MinuteClinic locations in Maryland, including clinics in select CVS Pharmacy stores.

"The new MinuteClinic locations inside Target will offer the same scope of services available to patients at all our other clinics in Maryland and nationwide," said Andrew Sussman, M.D., president of MinuteClinic, and EVP and associate chief medical officer of CVS Health. "In addition, some services will be new to Target guests, including treatment for minor sprains and strains, contraceptive care and smoking cessation counseling." 

With the new MinuteClinic in Target locations, Sussman says MinuteClinic can continue to play a complementary role in working with primary care providers. MinuteClinic locations in Maryland are affiliated with MedStar Health and University of Maryland Medical System.

"About 50 percent of MinuteClinic visits occur on evenings, weekends and holidays when patients may not be able to get an appointment with their primary care provider and otherwise may need to choose more expensive emergency department or urgent care options," he said. "Also, approximately half of the patients seen at MinuteClinic are 'medically homeless' and do not have a personal physician."

In December, CVS Health acquired all Target pharmacies (1,672 locations across 47 states) and retail clinics (79 locations in seven states). Target-based pharmacy locations are being rebranded CVS Pharmacy over the next several months and will operate through a store-within-a-store format. Target clinic locations are being rebranded as MinuteClinic over the next few months as well.  

The MinuteClinic walk-in medical clinics inside Target stores in Maryland operate from 9:00 a.m. to 7:30 p.m., Monday through Friday (Annapolis and Baltimore locations close at 7 p.m.) and from 9 a.m. to 4 p.m., Saturday and 9 a.m. to 4 p.m. Sunday (Annapolis and Baltimore locations open at 11 a.m.).

MinuteClinic locations inside Maryland Target stores include:

  • Annapolis:  1911 Towne Centre Blvd.
  • Baltimore:  3559 Boston St.
  • Bel Air:  580 Marketplace Dr.
  • Cockeysville:  9901 York Rd.
  • Ellicott City:  4390 Montgomery Rd.
  • Nottingham:  5230 Campbell Blvd.
  • Silver Spring:  12000 Cherry Hill Rd.
  • Towson:  1238 Putty Hill Ave. 
     

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Lupin gets FDA approval for Vfend generic

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration has approved Lupin’s U.S. subsidiary Gavis’ generic Vfend (voriconazole), the company announced Monday. The drug is indicated to treat invasive aspergillosis, esophageal candidiasis and other serious invasive fungal infections. 
 
Lupin’s generic will be available as 50- and 200-mg tablets, and as a 40-mg/mL oral suspension. The tablets had U.S. sales $92.8 million and the oral suspension had $15.9 million in sales, according to IMS Health estimates as of March 2016.  
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Allergan’s Byvalson

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration has approved Allergan’s Byvalson (nebivolol 5 mg and valsartan 80 mg) tablets, the company announced Monday. The drug is indicated to treat hypertension to lower blood pressure, and the company said it is the first fixed-dose combination of a beta-blocker and an angiotensin II receptor blocker in the U.S. 
 
“Achieving blood pressure control is critical to reducing the risk of serious and life-threatening cardiovascular events,” Allergan chief R&D officer David Nicholson said. “There remains a need for new therapies, as observed by the nearly half of patients in the U.S. who remain uncontrolled. We are pleased with the FDA approval of Byvalson, which will provide physicians a new fixed-dose combination therapy treatment option for patients affected by hypertension.”
 
Allergan expects Byvalson to be available in the second half of 2016. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?